| 10.8 0.2 (1.89%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.42 | 1-year : | 16.11 |
| Resists | First : | 12.35 | Second : | 13.8 |
| Pivot price | 11.28  |
|||
| Supports | First : | 10.01 | Second : | 8.32 |
| MAs | MA(5) : | 10.75 |
MA(20) : | 11.66 |
| MA(100) : | 10.98 |
MA(250) : | 11.81 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 19.3 |
D(3) : | 21.2 |
| RSI | RSI(14): 43.6 |
|||
| 52-week | High : | 18.23 | Low : | 8.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ITOS ] has closed above bottom band by 33.8%. Bollinger Bands are 52.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.91 - 10.95 | 10.95 - 10.99 |
| Low: | 10.44 - 10.49 | 10.49 - 10.53 |
| Close: | 10.72 - 10.8 | 10.8 - 10.87 |
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Sat, 13 Apr 2024
ITeos Therapeutics, Inc. (ITOS) Tops Q4 Earnings and Revenue Estimates - Yahoo Movies UK
Sun, 07 Apr 2024
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at ... - GlobeNewswire
Mon, 01 Apr 2024
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Expands By 11.7% - MarketBeat
Wed, 13 Mar 2024
ITOS Stock Quote Price and Forecast - CNN
Wed, 06 Mar 2024
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors - Yahoo Finance
Wed, 06 Mar 2024
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 2.479e+007 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 1,800 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.4668e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 171.6 % |
| Return on Equity (ttm) | -13 % |
| Qtrly Rev. Growth | 1.26e+007 % |
| Gross Profit (p.s.) | -84.04 |
| Sales Per Share | -15.29 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -104 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.71 |
| Price to Cash Flow | 0.8 |
| Dividend | 0 |
| Forward Dividend | 2.05e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|